Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis

References

• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. ATS and ERS. Am. J. Respir. Crit. Care Med.161, 646–664 (2000).
   Google Scholar
• The Japanese Respiratory Society, Committee for Formulation of Diffuse Pulmonary Disease Diagnosis and Treatment Guidelines: Idiopathic Interstitial Pneumonias – Guide to Diagnosis and Treatment. The Japanese Respiratory Society, Nankodo, Tokyo (2004) (In Japanese).
   Google Scholar
• Ohno S, Nakaya T, Bando M, Sugiyama Y. Nationwide epidemiological survey of patients with idiopathic interstitial pneumonias using clinical personal records. Records of Ministry of Health, Labor and Welfare of Japan in 2006, Japan, 46–54 (2007).
   Google Scholar
• Chiba H, Hayashi N, Takahashi H. Epidemiological survey of patients with idiopathic interstitial pneumonias using clinical personal records in Hokkaido. Records of Ministry of Health, Labor and Welfare of Japan in 2008, Japan, 39–46 (2009).
   Google Scholar
• Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.174, 810–816 (2006).
   PubMed Web of Science ®Google Scholar
• Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med.341(17), 1264–1269 (1999).
   PubMed Web of Science ®Google Scholar
• Azuma A, Usuki J. Novel therapy for idiopathic pulmonary fibrosis – how to evaluate the efficacy? Respir. Med.1, 75–81 (2008).
   Google Scholar
• Margolin SB, Lefkowitz S. Pirfenidone: a novel pharmacologic agent for prevention and resolution of lung fibrosis. FASEB J.8, A382 (1994).
   Web of Science ®Google Scholar
• Pirespa®, package insert. Shionogi & Co., Ltd, Japan.
   Google Scholar
• Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med.125(6), 779–785 (1995).
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther.291(1), 367–373 (1999).
   PubMed Web of Science ®Google Scholar
• Tada S, Nakamuta M, Enjoji M et al. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin. Exp. Pharmacol. Physiol.28(7), 522–527 (2001).
   PubMed Web of Science ®Google Scholar
• Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int.54(1), 99–109 (1998).
   PubMed Web of Science ®Google Scholar
• Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am. J. Physiol.276(2), L311–L318 (1999).
   PubMed Web of Science ®Google Scholar
• Kakugawa T, Mukae H, Hayashi T et al. Pirfenidone attenuates expression of HSP47 in murine bleomysin-induced pulmonary fibrosis. Eur. Respir. J.24(1), 57–65 (2004).
   PubMed Web of Science ®Google Scholar
• Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R. Pirfenidone suppresses tumor necrosis factor-a, enhances interleukin-10 and protects mice from endotoxic shock. Eur. J. Pharmacol.446(1–3), 167–176 (2002).
   PubMed Web of Science ®Google Scholar
• Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J. Exp. Med.170(3), 655–663 (1989).
   PubMed Web of Science ®Google Scholar
• Arai T, Abe K, Matsuoka H et al. Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol.278, L914–L922 (2000).
   PubMed Web of Science ®Google Scholar
• Oku H, Shimizu T, Kawabata T et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol.590, 400–408 (2008).
   PubMed Web of Science ®Google Scholar
• Internal data of Shiongi and Co., Ltd. [In vitro study of pirfenidone in cultured cell lines.] [Reference No. 200801770] (Article in Japanese).
   Google Scholar
• Mitani Y, Sato K, Muramoto Y et al. Superoxide scavenging activity of pirfenidone–iron complex. Biochem. Biophys. Res. Commun.372, 19–23 (2008).
   PubMed Web of Science ®Google Scholar
• Oku H. 7. A novel antifibrotic agent pirfenidone, 1) Antifibrotic mechanism of pirfenidone. Medicine Drug J.45(7), 120–125 (2009).
   Google Scholar
• Rubino CM, Bhavnani SM, Ambrose PG et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm. Pharmacol. Ther.22, 279–285 (2009).
   PubMed Web of Science ®Google Scholar
• Internal data of Shiongi and Co., Ltd. (Identification of CYP molecular species involved in oxidative metabolism) [Reference No. 200801762] (Article in Japanese).
   Google Scholar
• Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med.159, 1061–1069 (1999).
   PubMed Web of Science ®Google Scholar
• Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med.41, 1118–1123 (2002).
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E et al.; members of Research Group for Diffuse Lung Diseases in Japan. A double blind and placebo-controlled clinical study of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.171, 1040–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Homma Y, Saiki S, Doi O et al. Clinical Diagnostic Criteria for Idiopathic Interstitial Pneumonia (3rd Revised Ed.). Diffuse Pulmonary Disease Research Group’s, The Ministry of Health and Welfare of Japan, Japan, 83–88 (1992)
   Google Scholar
• Taniguchi H, Ebina M, Knodoh Y et al.; Pirfenidone Clinical Study Group in Japan. Pirfenidone in Idiopathic Pulmonary Fibrosis: a Phase III clinical trial in Japan. Eur. Respir. J.35, 821–829 (2010).
   PubMed Web of Science ®Google Scholar
• Ebina M, Kimura Y, Ohta H et al.; Clinical Study Group of Pirfenidone in Japan. Enhanced effects of pirfenidone on the early phase of idiopathic pulmonary fibrosis. Presented at: ERS 19th Annual Congress. Vienna, Austria, 12–16 September 2009 (Poster 666).
   Google Scholar
• Noble PW, Albera C, Bradford W et al. The CAPACITY (CAP) trials: randomized, double-blind, placebo-controlled, Phase III trials of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF). Presented at: American Thoracic Society Annual Conference. San Diego, CA, USA, 15–20 May 2009 (Abstract 216).
   Google Scholar
• de Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat. Drug Discov.9, 129–140 (2010).
   Google Scholar
• de Bois R, Albera C, Bradford W et al. Pirfenidone treatment for IPF comprehensive analysis of safety. Presented at: ERS 19th Annual Congress. Vienna, Austria, 12–16 September 2009 (Abstract 2823).
   Google Scholar
• Demedts M, Behr J, Buhl R et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med.353, 2229–2242 (2005).
   PubMed Web of Science ®Google Scholar